<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>DYRENIUM- triamterene capsule </strong><br>Carilion Materials Management<br></p></div>
<h1>DYRENIUM (triamterene USP) Capsules 50 mg and 100 mg potassium-sparing
diuretic
        <span class="Sup">®</span>
</h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Warning">
<a name="LINK_8427d45d-44e1-412a-934c-2810f7224f9c"></a><a name="section-1"></a><p></p>
<h1><span class="Bold">Warnings</span></h1>
<p class="First">Abnormal elevation of serum potassium levels (greater than or equal to 5.5 mEq/liter) can occur with all potassium-sparing agents, including Dyrenium. <span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">Hyperkalemia</span> is more likely to occur in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> and <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> (even without evidence of <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>), and in the elderly or severely ill. Since uncorrected <span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">hyperkalemia</span> may be fatal, serum potassium levels must be monitored at frequent intervals especially in patients receiving Dyrenium, when dosages are changed or with any illness that may influence renal function.</p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="LINK_36061691-9874-49e4-bb56-aaeb1c9cda04"></a><a name="section-1"></a><p></p>
<h1><span class="Bold">DESCRIPTION</span></h1>
<p class="First">Each capsule for oral use, with opaque red cap and body, contains Triamterene USP, 50 or 100 mg, and is imprinted with the product name, DYRENIUM, strength (50 mg or 100 mg) and WPC 002 (for the 50-mg strength) and WPC 003 (for the 100-mg strength). Inactive ingredients consist of D&amp;C Red No. 33, FD&amp;C Yellow No. 6, Gelatin NF, Lactose NF, Magnesium Stearate NF, Sodium Lauryl Sulfate NF, Titanium Dioxide USP and Silicon Dioxide NF.</p>
<p>Triamterene is 2,4,7-triamino-6-phenyl-pteridine:</p>
<br><div class="Figure"><img alt="Triamterene Chemical Structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=ffe24e3d-cfe8-4d5a-8213-69f0bbc9f4d5&amp;name=dyrenium-1.jpg"></div>
<br><p>Its molecular weight is 253.27. At 50°C, triamterene is slightly soluble in water. It is soluble in dilute <span class="product-label-link" type="condition" conceptid="4184927" conceptname="Ammonia">ammonia</span>, dilute aqueous sodium hydroxide and dimethylformamide. It is sparingly soluble in methanol.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="LINK_4184c310-11a6-481d-b3ca-20dcf14edc5e"></a><a name="section-2"></a><p></p>
<h1><span class="Bold">CLINICAL PHARMACOLOGY</span></h1>
<p class="First">Triamterene has a unique mode of action; it inhibits the reabsorption of sodium ions in exchange for potassium and hydrogen ions at that segment of the distal tubule under the control of adrenal mineralocorticoids (especially aldosterone). This activity is not directly related to aldosterone secretion or antagonism; it is a result of a direct effect on the renal tubule.</p>
<p>The fraction of filtered sodium reaching this distal tubular exchange site is relatively small, and the amount which is exchanged depends on the level of mineralocorticoid activity. Thus, the degree of natriuresis and <span class="product-label-link" type="condition" conceptid="79936" conceptname="Polyuria">diuresis</span> produced by inhibition of the exchange mechanism is necessarily limited. Increasing the amount of available sodium and the level of mineralocorticoid activity by the use of more proximally acting diuretics will increase the degree of <span class="product-label-link" type="condition" conceptid="79936" conceptname="Polyuria">diuresis</span> and potassium conservation.</p>
<p>Triamterene occasionally causes increases in serum potassium which can result in <span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">hyperkalemia</span>. It does not produce <span class="product-label-link" type="condition" conceptid="438730" conceptname="Alkalosis">alkalosis</span>, because it does not cause excessive excretion of titratable acid and ammonium.</p>
<p>Triamterene has been shown to cross the placental barrier and appear in the cord blood of animals.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_7005347d-65e4-4730-bc2c-7d280f9c6fd2"></a><a name="section-2.1"></a><p></p>
<h2><span class="Bold">Pharmacokinetics</span></h2>
<p class="First">Onset of action is 2 to 4 hours after ingestion. In normal volunteers the mean peak serum levels were 30 ng/mL at 3 hours. The average percent of drug recovered in the urine (0 to 48 hours) was 21%. Triamterene is primarily metabolized to the sulfate conjugate of hydroxytriamterene. Both the plasma and urine levels of this metabolite greatly exceed triamterene levels. Triamterene is rapidly absorbed, with somewhat less than 50% of the oral dose reaching the urine. Most patients will respond to Dyrenium (triamterene) during the first day of treatment.</p>
<p>Maximum therapeutic effect, however, may not be seen for several days. Duration of <span class="product-label-link" type="condition" conceptid="79936" conceptname="Polyuria">diuresis</span> depends on several factors, especially renal function, but it generally tapers off 7 to 9 hours after administration.</p>
</div>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="LINK_3de2326c-8bcc-4989-8219-fe28f23ba3a3"></a><a name="section-3"></a><p></p>
<h1><span class="Bold">INDICATIONS AND USAGE</span></h1>
<p class="First">Dyrenium (triamterene) is indicated in the treatment of <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span> associated with <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span>, cirrhosis of the liver and the <span class="product-label-link" type="condition" conceptid="195314" conceptname="Nephrotic syndrome">nephrotic syndrome</span>; steroid-induced <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>, idiopathic <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span> and <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span> due to secondary hyperaldosteronism.</p>
<p>Dyrenium may be used alone or with other diuretics, either for its added <span class="product-label-link" type="condition" conceptid="79936" conceptname="Polyuria">diuretic effect</span> or its potassium-sparing potential. It also promotes increased <span class="product-label-link" type="condition" conceptid="79936" conceptname="Polyuria">diuresis</span> when patients prove resistant or only partially responsive to thiazides or other diuretics because of secondary hyperaldosteronism.</p>
<p>. The routine use of diuretics in an otherwise healthy woman is inappropriate and exposes mother and fetus to unnecessary hazard. Diuretics do not prevent development of <span class="product-label-link" type="condition" conceptid="439393" conceptname="Pre-eclampsia">toxemia of pregnancy</span>, and there is no satisfactory evidence that they are useful in the treatment of developed toxemia.
                            <span class="Italics">Usage in Pregnancy</span></p>
<p><span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">Edema</span> during pregnancy may arise from pathological causes or from the physiologic and mechanical consequences of pregnancy. Diuretics are indicated in pregnancy (however, see below) when <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span> is due to pathologic causes, just as they are in the absence of pregnancy. <span class="product-label-link" type="condition" conceptid="4087149" conceptname="Dependent edema">Dependent edema</span> in pregnancy, resulting from restriction of venous return by the expanded uterus, is properly treated through elevation of the lower extremities and use of support hose; use of diuretics to lower intravascular volume in this case is illogical and unnecessary. There is <span class="product-label-link" type="condition" conceptid="434004" conceptname="Hypervolemia">hypervolemia</span> during <span class="product-label-link" type="condition" conceptid="4128331" conceptname="Pregnancy">normal pregnancy</span> which is harmful to neither the fetus nor the mother (in the absence of cardiovascular disease), but which is associated with <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>, including <span class="product-label-link" type="condition" conceptid="4043107" conceptname="Anasarca">generalized edema</span>, in the majority of pregnant women. If this <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span> produces <span class="product-label-link" type="condition" conceptid="4090431" conceptname="Discomfort">discomfort</span>, increased recumbency will often provide relief. In rare instances, this <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span> may cause extreme <span class="product-label-link" type="condition" conceptid="4090431" conceptname="Discomfort">discomfort</span> which is not relieved by rest. In these cases, a short course of diuretics may provide relief and may be appropriate.
                            <a href="#LINK_da02ee5e-0e1e-4a80-9a86-5afab375eb30">PRECAUTIONS</a></p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="LINK_8d8c1a26-894b-4a19-ae9e-3ea573bb4045"></a><a name="section-4"></a><p></p>
<h1><span class="Bold">CONTRAINDICATIONS</span></h1>
<p class="First"><span class="product-label-link" type="condition" conceptid="4090272" conceptname="Anuria">Anuria</span>. Severe or progressive kidney disease or dysfunction, with the possible exception of <span class="product-label-link" type="condition" conceptid="195314" conceptname="Nephrotic syndrome">nephrosis</span>. Severe <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic disease</span>. <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span> to the drug or any of its components.</p>
<p>Dyrenium (triamterene) should not be used in patients with pre-existing elevated serum potassium, as is sometimes seen in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span> or <span class="product-label-link" type="condition" conceptid="4261202" conceptname="Uremia">azotemia</span>, or in patients who develop <span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">hyperkalemia</span> while on the drug. Patients should not be placed on dietary potassium supplements, potassium salts or potassium-containing salt substitutes in conjunction with Dyrenium.</p>
<p>Dyrenium should not be given to patients receiving other potassium-sparing agents, such as spironolactone, amiloride hydrochloride, or other formulations containing triamterene. Two <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">deaths</span> have been reported in patients receiving concomitant spironolactone and Dyrenium or Dyazide . Although dosage recommendations were exceeded in one case and in the other serum electrolytes were not properly monitored, these two drugs should not be given concomitantly.
                            <span class="Sup">®</span></p>
<div class="Warning">
<a name="LINK_2af6dee6-c23d-4ffe-9b08-25d490da6be1"></a><a name="section-4.1"></a><p></p>
<h2><span class="Bold">WARNINGS</span></h2>
<p class="First">Abnormal elevation of serum potassium levels (greater than or equal to 5.5 mEq/liter) can occur with all potassium-sparing agents, including Dyrenium. <span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">Hyperkalemia</span> is more likely to occur in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> and <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> (even without evidence of <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>), and in the elderly or severely ill. Since uncorrected <span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">hyperkalemia</span> may be fatal, serum potassium levels must be monitored at frequent intervals especially in patients receiving Dyrenium, when dosages are changed or with any illness that may influence renal function.</p>
</div>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="LINK_916d29c7-35e6-4ebd-96d1-c07fd4e7b5a1"></a><a name="section-5"></a><p></p>
<h1></h1>
<p class="First">There have been isolated reports of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reactions</span>; therefore, patients should be observed regularly for the possible occurrence of <span class="product-label-link" type="condition" conceptid="40528016" conceptname="Disorder of hematopoietic system">blood dyscrasias</span>, <span class="product-label-link" type="condition" conceptid="4352876" conceptname="Liver damage">liver damage</span> or other idiosyncratic reactions.</p>
<p>Periodic BUN and serum potassium determinations should be made to check kidney function, especially in patients with suspected or confirmed <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal insufficiency</span>. It is particularly important to make serum potassium determinations in elderly or diabetic patients receiving the drug; these patients should be observed carefully for possible serum potassium increases.</p>
<p>If <span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">hyperkalemia</span> is present or suspected, an electrocardiogram should be obtained. If the ECG shows no widening of the QRS or <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">arrhythmia</span> in the presence of <span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">hyperkalemia</span>, it is usually sufficient to discontinue Dyrenium (triamterene) and any potassium supplementation, and substitute a thiazide alone. Sodium polystyrene sulfonate (Kayexalate , Sanofi Synthelabo) may be administered to enhance the excretion of excess potassium. For <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachyarrhythmia</span>, infuse 44 mEq of sodium <span class="product-label-link" type="condition" conceptid="4285456" conceptname="Bicarbonate">bicarbonate</span> or 10 mL of 10% calcium gluconate or calcium chloride over several minutes. For <span class="product-label-link" type="condition" conceptid="321042" conceptname="Cardiac arrest">asystole</span>, <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span> or A-V block transvenous pacing is also recommended.
                            <span class="Sup">®</span><span class="Bold">The presence of a widened <span class="product-label-link" type="condition" conceptid="4064625" conceptname="QRS complex feature">QRS complex</span> or <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">arrhythmia</span> in association with <span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">hyperkalemia</span> requires prompt additional therapy.</span></p>
<p>The effect of calcium and sodium <span class="product-label-link" type="condition" conceptid="4285456" conceptname="Bicarbonate">bicarbonate</span> is transient and repeated administration may be required. When indicated by the clinical situation, excess K+ may be removed by dialysis or oral or rectal administration of Kayexalate . Infusion of glucose and insulin has also been used to treat <span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">hyperkalemia</span>.
                            <span class="Sup">®</span></p>
</div>
<div class="Section" data-sectionCode="34072-9">
<a name="LINK_da02ee5e-0e1e-4a80-9a86-5afab375eb30"></a><a name="section-6"></a><p></p>
<h1><span class="Bold">PRECAUTIONS General
                            <br></span></h1>
<p class="First">Dyrenium (triamterene) tends to conserve potassium rather than to promote the excretion as do many diuretics and, occasionally, can cause increases in serum potassium which, in some instances, can result in <span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">hyperkalemia</span>. In rare instances, <span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">hyperkalemia</span> has been associated with cardiac irregularities.</p>
<p><span class="product-label-link" type="condition" conceptid="4022093" conceptname="Electrolyte imbalance">Electrolyte imbalance</span> often encountered in such diseases as <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span>, <span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">renal disease</span> or cirrhosis may be aggravated or caused independently by any effective diuretic agent includingDyrenium. The use of full doses of a diuretic when salt intake is restricted can result in a low-salt syndrome.</p>
<p>Triamterene can cause mild nitrogen retention, which is reversible upon withdrawal of the drug, and is seldom observed with intermittent (every-other-day) therapy.</p>
<p>Triamterene may cause a decreasing alkali reserve, with the possibility of <span class="product-label-link" type="condition" conceptid="4245042" conceptname="Metabolic acidosis">metabolic acidosis</span>.</p>
<p>By the very nature of their illness, cirrhotics with <span class="product-label-link" type="condition" conceptid="200527" conceptname="Splenomegaly">splenomegaly</span> sometimes have marked variations in their blood. Since triamterene is a weak folic acid antagonist, it may contribute to the appearance of <span class="product-label-link" type="condition" conceptid="435789" conceptname="Megaloblastic anemia">megaloblastosis</span> in cases where folic acid stores have been depleted. Therefore, periodic blood studies in these patients are recommended. They should also be observed for exacerbations of underlying liver disease.</p>
<p>Triamterene has elevated uric acid, especially in persons predisposed to <span class="product-label-link" type="condition" conceptid="74892" conceptname="Articular gout">gouty arthritis</span>.</p>
<p>Triamterene has been reported in <span class="product-label-link" type="condition" conceptid="201620" conceptname="Kidney stone">renal stones</span> in association with other calculus components. Dyrenium should be used with caution in patients with histories of <span class="product-label-link" type="condition" conceptid="201620" conceptname="Kidney stone">renal stones</span>.</p>
<div class="Section" data-sectionCode="34076-0">
<a name="LINK_47848173-50cb-492b-a10d-db6b009e0b87"></a><a name="section-6.1"></a><p></p>
<h2><span class="Bold">Information for Patients</span></h2>
<p class="First">To help avoid <span class="product-label-link" type="condition" conceptid="4152197" conceptname="Stomach ache">stomach upset</span>, it is recommended that the drug be taken after meals.</p>
<p>If a single daily dose is prescribed, it may be preferable to take it in the morning to minimize the effect of increased frequency of urination on nighttime sleep.</p>
<p>If a dose is missed, the patient should not take more than the prescribed dose at the next dosing interval.</p>
</div>
<div class="Section" data-sectionCode="34075-2">
<a name="LINK_b1de749a-5726-4248-beee-ac81feb92d83"></a><a name="section-6.2"></a><p></p>
<h2><span class="Bold">Laboratory Tests</span></h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">Hyperkalemia</span> will rarely occur in patients with adequate urinary output, but it is a possibility if large doses are used for considerable periods of time. If <span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">hyperkalemia</span> is observed, Dyrenium (triamterene) should be withdrawn. The normal adult range of serum potassium is 3.5 to 5.0 mEq per liter, with 4.5 mEq often being used for a reference point. Potassium levels persistently above 6 mEq per liter require careful observation and treatment. Normal potassium levels tend to be higher in neonates (7.7 mEq per liter) than in adults. Serum potassium levels do not necessarily indicate true body potassium concentration. A rise in plasma pH may cause a decrease in plasma potassium concentration and an increase in the intracellular potassium concentration. Because Dyrenium conserves potassium, it has been theorized that in patients who have received intensive therapy or been given the drug for <span class="product-label-link" type="condition" conceptid="4088438" conceptname="Prolonged periods">prolonged periods</span>, a rebound kaliuresis could occur upon abrupt withdrawal. In such patients, withdrawal of Dyrenium should be gradual.</p>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="LINK_5683751d-b3fe-4ec1-80c6-416663b79922"></a><a name="section-6.3"></a><p></p>
<h2><span class="Bold">Drug Interactions</span></h2>
<p class="First">Caution should be used when lithium and diuretics are used concomitantly because diuretic-induced sodium loss may reduce the renal clearance of lithium and increase serum lithium levels with risk of <span class="product-label-link" type="condition" conceptid="433667" conceptname="Poisoning by tetanus vaccine">lithium toxicity</span>. Patients receiving such combined therapy should have serum lithium levels monitored closely and the lithium dosage adjusted if necessary.</p>
<p>A possible interaction resulting in <span class="product-label-link" type="condition" conceptid="197320" conceptname="Acute renal failure syndrome">acute renal failure</span> has been reported in a few subjects when indomethacin, a nonsteroidal anti-inflammatory agent, was given with triamterene. Caution is advised in administering nonsteroidal anti-inflammatory agents with triamterene.</p>
<p>The effects of the following drugs may be potentiated when given together with triamterene: antihypertensive medication, other diuretics, preanesthetic and anesthetic agents, skeletal muscle relaxants (nondepolarizing).</p>
<p>Potassium-sparing agents should be used with caution in conjunction with angiotensin-converting enzyme (ACE) inhibitors due to an increased risk of <span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">hyperkalemia</span>.</p>
<p>The following agents, given together with triamterene, may promote serum potassium accumulation and possibly result in <span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">hyperkalemia</span> because of the potassium-sparing nature of triamterene, especially in patients with <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal insufficiency</span>: blood from blood bank (may contain up to 30 mEq of potassium per liter of plasma or up to 65 mEq per liter of whole blood when stored for more than 10 days); low-salt milk (may contain up to 60 mEq of potassium per liter); potassium-containing medications (such as parenteral penicillin G potassium); salt substitutes (most contain substantial amounts of potassium).</p>
<p>Dyrenium (triamterene) may raise blood glucose levels; for adult-onset <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>, dosage adjustments of hypoglycemic agents may be necessary during and/or after therapy; concurrent use with chlorpropamide may increase the risk of severe <span class="product-label-link" type="condition" conceptid="4232311" conceptname="Hyponatremia">hyponatremia</span>.</p>
</div>
<div class="Section" data-sectionCode="34074-5">
<a name="LINK_900cedc2-4d1f-4689-9117-0a56956bbd2c"></a><a name="section-6.4"></a><p></p>
<h2>Drug/Laboratory Test Interactions</h2>
<p class="First">Triamterene and quinidine have similar fluorescence spectra;
thus, triamterene will interfere with the fluorescent measurement of quinidine.</p>
</div>
<div class="Section" data-sectionCode="34083-6">
<a name="LINK_b5006e73-0a2a-47cc-bd30-1dbdf93c7508"></a><a name="section-6.5"></a><p></p>
<h2>Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<p class="First">In studies conducted under the auspices of the National Toxicology Program, groups of rats were fed diets containing 0, 150, 300 or 600 ppm of triamterene, and groups of mice were fed diets containing 0, 100, 200 or 400 ppm triamterene. Male and female rats exposed to the highest tested concentration received triamterene at about 25 and 30 mg/kg/day, respectively. Male and female mice exposed to the highest tested concentration received triamterene at about 45 and 60 mg/kg/day, respectively.
                                    <span class="Bold">Carcinogenesis:</span></p>
<p>There was an increased incidence of hepatocellular neoplasia (primarily <span class="product-label-link" type="condition" conceptid="4106411" conceptname="Adenofibroma">adenomas</span>) in male and female mice at the highest dosage level. These doses represent 7.5X and 10X the Maximum Recommended Human Dose (MRHD) of 300 mg/kg/day (or 6 mg/kg/day based on a 50 kg patient) for male and female mice, respectively, when based on body weight and 0.7X and 0.9X the MRHD when based on body-surface area.</p>
<p>Although hepatocellular neoplasia (exclusively <span class="product-label-link" type="condition" conceptid="4106411" conceptname="Adenofibroma">adenomas</span>) in the rat study was limited to triamterene-exposed males, incidence was not dose dependent and there was no statistically significant difference from control incidence at any dose level.</p>
<p>Triamterene was not mutagenic in bacteria (<span class="product-label-link" type="condition" conceptid="4235289" conceptname="Salmonellosis">Salmonella</span> typhimurium <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> TA98, TA100, TA1535 or TA1537) with or without metabolic activation. It did not induce chromosomal aberrations in Chinese hamster ovary (CHO) cells with or without metabolic activation, but it did induce sister chromatid exchanges in CHO cells with and without metabolic activation.
                                    <span class="Bold">Mutagenesis:</span><span class="Italics">in vitro</span><span class="Italics">in vitro</span></p>
<p>: Studies of the effects of triamterene on animal reproductive function have not been conducted.
                                    <span class="Bold">Impairment of Fertility</span></p>
</div>
<div class="Section" data-sectionCode="42228-7">
<a name="LINK_43bdb964-66fd-4061-8eb6-51988e27eaae"></a><a name="section-6.6"></a><p></p>
<h2>Pregnancy: Category C</h2>
<div class="Section" data-sectionCode="34077-8">
<a name="LINK_10bd433b-0103-4036-8bf0-e38773037e11"></a><a name="section-6.6.1"></a><p></p>
<h3><span class="Italics">Teratogenic Effects:</span></h3>
<p class="First">Reproduction studies have been performed in rats at doses as high as 20 times the Maximum Recommended Human Dose (MRHD) on the basis of body weight, and 6 times the MRHD on the basis of body-surface area, without evidence of harm to the fetus due to triamterene. Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed.</p>
</div>
<div class="Section" data-sectionCode="34078-6">
<a name="LINK_96685a9f-483c-452d-8210-27665a9e6471"></a><a name="section-6.6.2"></a><p></p>
<h3><span class="Italics">Nonteratogenic Effects:</span></h3>
<p class="First">Triamterene has been shown to cross the placental barrier and appear in cord blood. The use of triamterene in pregnant women requires that the anticipated benefits be weighed against possible hazards to the fetus. These possible hazards include adverse reactions which have occurred in the adult.</p>
</div>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="LINK_9bf1c6df-892a-43f1-a1a0-9e0e891a9a53"></a><a name="section-6.7"></a><p></p>
<h2>Nursing Mothers:</h2>
<p class="First">Triamterene has not been studied in nursing mothers. Triamterene
appears in animal milk and is likely present in human milk. If use of the
drug product is deemed essential, the patient should stop nursing.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="LINK_6c8cfd29-c0a5-4f08-bdea-22d1fb330204"></a><a name="section-6.8"></a><p></p>
<h2>Pediatric Use:</h2>
<p class="First">Safety and effectiveness in pediatric
patients have not been established.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="LINK_c0cada53-26f2-46df-8e59-d03d116e63c0"></a><a name="section-7"></a><p></p>
<h1>ADVERSE REACTIONS</h1>
<p class="First">Adverse effects are listed in decreasing order of frequency; however, the most serious adverse effects are listed first, regardless of frequency. All adverse effects occur rarely (that is, 1 in 1000, or less).</p>
<p><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span>: <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, <span class="product-label-link" type="condition" conceptid="4080920" conceptname="Phytophotodermatitis">photosensitivity</span>.</p>
<p>Metabolic: <span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">hyperkalemia</span>, <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span>.</p>
<p>Renal: <span class="product-label-link" type="condition" conceptid="4261202" conceptname="Uremia">azotemia</span>, elevated BUN and creatinine, <span class="product-label-link" type="condition" conceptid="201620" conceptname="Kidney stone">renal stones</span>, <span class="product-label-link" type="condition" conceptid="4102631" conceptname="Acute interstitial nephritis">acute interstitial nephritis</span> (rare), <span class="product-label-link" type="condition" conceptid="197320" conceptname="Acute renal failure syndrome">acute renal failure</span> (one case of <span class="product-label-link" type="condition" conceptid="198185" conceptname="Chronic renal failure">irreversible renal failure</span> has been reported).</p>
<p>Gastrointestinal: <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span> and/or liver enzyme abnormalities, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>.</p>
<p>Hematologic: <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span>, <span class="product-label-link" type="condition" conceptid="435789" conceptname="Megaloblastic anemia">megaloblastic anemia</span>.</p>
<p>Central Nervous System: <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span>, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">dry mouth</span>.</p>
<table>
<col>
<tbody class="Headless"><tr class="First Last"><td class="Botrule Lrule Rrule Toprule"><p class="First"> 
                                            <span class="Underline">To report SUSPECTED ADVERSE REACTIONS, contact WellSpring Pharmaceutical Corporation at 1-866-337-4500 or FDA at 1-800-FDA-1088 or</span><a href="#LINK_00000000-0000-0000-0000-000000000000">www.fda.gov/medwatch</a><span class="Underline">.</span></p></td></tr></tbody>
</table>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="LINK_5c57d178-d006-46c2-856f-a016108539b8"></a><a name="section-8"></a><p></p>
<h1>OVERDOSAGE</h1>
<p class="First">In the event of overdosage, it can be theorized that electrolyte
imbalance would be the major concern, with particular attention to possible
<span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">hyperkalemia</span>. Other symptoms that might be seen would be <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>,
other G.I. disturbances and <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span>. It is conceivable that some <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>
could occur. As with an <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> of any drug, immediate evacuation of the
stomach should be induced through <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">emesis</span> and gastric lavage. Careful evaluation
of the electrolyte pattern and fluid balance should be made. There is no specific
antidote.</p>
<p>Reversible <span class="product-label-link" type="condition" conceptid="197320" conceptname="Acute renal failure syndrome">acute renal failure</span> following
ingestion of 50 tablets of a product containing a combination of 50 mg triamterene
and 25 mg hydrochlorothiazide has been reported.</p>
<p>The
oral LD50 in mice is 380 mg/kg. The amount of drug in a single dose ordinarily
associated with symptoms of <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> or likely to be life-threatening is not
known.</p>
<p>Although triamterene is 67% protein bound, there
may be some benefit to dialysis in cases of overdosage.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="LINK_7bb9ac18-ad5e-46e5-b87a-0ac17cbfa526"></a><a name="section-9"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION</h1>
<p class="First"><span class="Bold">Adult Dosage</span></p>
<p>Dosage
should be titrated to the needs of the individual patient. When used alone,
the usual starting dose is 100 mg twice daily after meals. When combined with
another diuretic or antihypertensive agent, the total daily dosage of each
agent should usually be lowered initially and then adjusted to the patient’s
needs. The total daily dosage should not exceed 300 mg. Please refer to
                            <a href="#LINK_da02ee5e-0e1e-4a80-9a86-5afab375eb30">PRECAUTIONS−General.</a></p>
<p>When
Dyrenium (triamterene) is added to other diuretic therapy or when patients
are switched to Dyrenium from other diuretics, all potassium supplementation
should be discontinued.</p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="LINK_aebf5657-661b-4b2b-9243-6cb5033ba91c"></a><a name="section-10"></a><p></p>
<h1>HOW SUPPLIED</h1>
<p class="First">NDC:68151-1494-0 in a PACKAGE of 1 CAPSULES</p>
</div>
<div class="Section" data-sectionCode="44425-7">
<a name="LINK_42b8a184-165b-4132-8677-041336de05cd"></a><a name="section-11"></a><p></p>
<h1>STORAGE</h1>
<p class="First">Store at 25°C (77°F); excursions permitted to 15° - 30°C (59° - 86°F) [See USP Controlled Room Temperature]. Dispense in a tight, light resistant container.</p>
<p>50 mg 100s: NDC 65197-002-01</p>
<p>100 mg 100s: NDC 65197-003-01</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_bbfbbe0b-0dc0-4415-bf22-b81994d834d7"></a><a name="section-12"></a><p></p>
<h1></h1>
<p class="First">Manufactured for Sarasota, FL 34243 USA By WellSpring Pharmaceutical Canada Corp. Oakville, Ontario L6H 1M5 Canada</p>
<p>DATE OF ISSUANCE MARCH 2009</p>
<p>©WellSpring, 2009</p>
<br><br><span class="Bold">WellSpring Pharmaceutical Corporation</span><br><br><br><br><p>Rev. 03/09</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="LINK_69866d15-7192-4835-913c-31d368facaa1"></a><a name="section-13"></a><p></p>
<h1>Triamterene 50 mg capsules</h1>
<div class="Figure"><img alt="Label Image" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=ffe24e3d-cfe8-4d5a-8213-69f0bbc9f4d5&amp;name=68151-1494.jpg"></div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>DYRENIUM 		
					</strong><br><span class="contentTableReg">triamterene capsule</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:68151-1494(NDC:65197-002)</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>TRIAMTERENE</strong> (TRIAMTERENE) </td>
<td class="formItem">TRIAMTERENE</td>
<td class="formItem">50 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>D&amp;C RED NO. 33</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>FD&amp;C YELLOW NO. 6</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>GELATIN</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>LACTOSE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SODIUM LAURYL SULFATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>TITANIUM DIOXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SILICON DIOXIDE</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">RED (opaque red) </td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">CAPSULE</td>
<td class="formLabel">Size</td>
<td class="formItem">10mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">DYRENIUM;50;mg;DYRENIUM;WPC;002</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:68151-1494-0</td>
<td class="formItem">1  in 1 PACKAGE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA013174</td>
<td class="formItem">10/01/1999</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Carilion Materials Management
							(079239644)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Registrant - </span>Carilion Materials Management (079239644)</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Carilion Materials Management</td>
<td class="formItem"></td>
<td class="formItem">079239644</td>
<td class="formItem">REPACK(68151-1494)</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 10/2012<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>86bb7a01-9ff0-4bea-8643-e40f1a482700</div>
<div>Set id: ffe24e3d-cfe8-4d5a-8213-69f0bbc9f4d5</div>
<div>Version: 2</div>
<div>Effective Time: 20121008</div>
</div>
</div> <div class="DistributorName">Carilion Materials Management</div></p>
</body></html>
